Shareholder Voting Rights and Company Capital Structure

Written by Emily J. Thompson, Senior Investment Analyst

Source: Globenewswire

Updated: Aug 26 2025

0mins

Should l Buy ?

Source: Globenewswire

Company Overview: Nanobiotix is a clinical biotechnology company based in Paris, specializing in innovative therapeutic approaches to improve treatment outcomes for patients, particularly in oncology and central nervous system disorders.
Market Presence: The company is listed on Euronext Paris since 2012 and on Nasdaq since December 2020, with subsidiaries in locations including Cambridge, Massachusetts.
Patent Portfolio: Nanobiotix holds over 25 patent families related to three nanotechnology platforms aimed at enhancing bioavailability, biodistribution, and cancer treatment.
Voting Rights Information: As of July 31, 2025, Nanobiotix has 48,236,671 shares outstanding, with total voting rights calculated at 50,340,736 (theoretical) and 50,318,618 (exercisable).

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

GET FREE REAL TIME NOTIFICATIONS

Stock Monitor for NVDA?

Get Started Free

FREE STOCK RECOMMENDATIONS DAILY

Stock Bullish Tomorrow

Get Started Free

70% BACKTESTED ACCURACY!

Should I Buy NVDA?

Get Started Free